is tirzepatide being discontinued FDA Says Shortage of GLP-1 Over Did the FDA Ban Compounded

How is this medication used

During the treatment, the incidence rate of hypoglycemia was higher in the group without lifestyle intervention compared with that with lifestyle intervention (P for interaction =004)

People struggling to consume 90-100 grams of protein daily face higher risk

The European Medicines Agency has reviewed all available data on NAION with semaglutide, including data from non-clinical studies, clinical trials, post-marketing surveillance and the medical literature, and has concluded that NAION is a very rare side effect of semaglutide (meaning it may affect up to 1 in 1,000 people taking semaglutide) 3

Want to support your GLP-1 levels through what you eat

Efficacy and safety of the new appetite suppressant, liraglutide: a meta-analysis of randomized controlled trials